best peptides crossfit FAQ

Yes, but the benefit scales with training volume. Athletes sleeping 8+ hours and eating in a caloric surplus already have optimised endogenous GH production. Adding a growth hormone secretagogue amplifies that baseline, shortening recovery windows between high-volume blocks. The practical difference: an athlete might handle five training days weekly without peptides but sustain six days with a secretagogue, or maintain intensity across a second daily session that would otherwise require backing off. The mechanism works whether you're starting from optimal or suboptimal baselines. It's simply additive.

BPC-157 targets localised tissue repair more directly than systemic GH secretagogues. Dose 250–500mcg subcutaneously near the affected joint once or twice daily for 4–8 weeks. Pair it with TB-500 if range of motion is limited or scar tissue is present. TB-500's actin-binding mechanism prevents fibrosis and improves tissue extensibility. A GH secretagogue like MK-677 can run concurrently to support systemic collagen synthesis, but the tissue repair peptides address the injury site directly.

Growth hormone is lipolytic. It promotes fat oxidation by increasing hormone-sensitive lipase activity in adipocytes. Running a GH secretagogue during a caloric deficit preserves lean mass and accelerates fat loss compared to diet alone. MK-677 increases appetite significantly, which complicates adherence to a deficit, making GHRP-2 the better choice during weight cuts. Dose GHRP-2 post-training when appetite suppression from exercise is strongest, and avoid dosing first thing in the morning when hunger is already elevated.

Stop loading the injured tissue and consider BPC-157 for localized inflammation resolution. Shoulder impingement in CrossFit athletes typically stems from repetitive overhead work combined with inadequate scapular stabilization. BPC-157 administered subcutaneously near the injury site has shown in research contexts to reduce inflammatory cytokine expression and promote angiogenesis in damaged tendons. The compound won't fix poor movement mechanics or scapular dyskinesia. Those require dedicated rehab work. But it can accelerate the tissue healing phase once you've removed the aggravating stimulus. Expect early symptom improvement within 7–14 days if the protocol is effective.

Prioritize compounds with the longest research history and avoid dosing protocols that exceed what published studies have tested. BPC-157 and TB-500 have been studied in animal models for over two decades with minimal adverse effects reported at standard dosing ranges. Growth hormone secretagogues underwent Phase 1 and Phase 2 human trials that established safety profiles for short-to-medium-term use. The unknowns are long-term effects beyond what trial durations covered and individual variability in response. Practical risk mitigation: use the lowest effective dose, limit duration to defined intervention periods, work with a physician who can monitor relevant biomarkers, and source compounds from facilities that provide third-party purity verification.

Evaluate whether cortisol dysregulation or blunted growth hormone pulsatility is limiting adaptation. CrossFit athletes training five to six days per week often experience chronic elevation of evening cortisol that suppresses overnight GH secretion. Growth hormone secretagogues like CJC-1295 Ipamorelin restore this pulse by stimulating the pituitary without replacing endogenous production. Research contexts dose this combination at 100 mcg each before bed, five nights per week. The effect isn't immediate. Improved sleep quality typically appears within 3–7 days, but measurable changes in body composition take 8–16 weeks. This is not a substitute for managing training volume or addressing nutritional deficiencies.